Liu J, et al. - Given that the elimination of hepatitis B virus (HBV) infection is hindered by mother-to-child transmission (MTCT), researchers examined telbivudine (LdT) and tenofovir disoproxil fumarate (TDF), the two most common antiviral medicine for preventing MTCT, for their efficacy and safety in preventing HBV vertical transmission during the second to third trimester. In this prospective multicenter cohort study, they enrolled 893 mothers; of these, 857 (LdT/TDF/untreated group (NTx) = 396/325/136) completed consecutive follow-up with 854 infants (LdT/TDF/NTx = 395/323/136). Observations revealed good tolerability to LdT and TDF treatments with comparable treatment efficacy in reducing MTCT. Pregnant women with HBsAg >4 log₁₀ IU/mL showed a higher risk of MTCT.